title: Psoriasiform exfoliative erythroderma induced by golimumab.
abstract: Golimumab is a fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti-TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.
authors.affiliation: Department of Dermatology, Faculty of Medicine, Complejo Hospitalario Universitario, Santiago de Compostela, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Mateo
authors.forename: F J
authors.initials: FJ
authors.lastname: García-Martínez
authors.forename: D
authors.initials: D
authors.lastname: Sánchez-Aguilar
authors.forename: J
authors.initials: J
authors.lastname: Amarelo
authors.forename: J
authors.initials: J
authors.lastname: Toribio
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab